FFRangio System vs InVision Precision Cardiac Amyloid

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

FFRangio System

by CathWorks (acquired by Medtronic)

InVision Precision Cardiac Amyloid

by InVision Medical Technology

AI Verdict

Tool A, the FFRangio System, is designed to optimize PCI decisions for coronary artery disease using 3D FFR guidance from angiograms. Conversely, Tool B, InVision Precision Cardiac Amyloid, focuses on detecting cardiac amyloidosis from echocardiography studies. While both are cardiology AI tools, their distinct applications in interventional guidance versus diagnostic detection of specific conditions make them suitable for different clinical workflows and patient populations.

Choose FFRangio System if…

Choose the FFRangio System if your interventional cardiology practice requires real-time, non-invasive functional assessment of coronary artery disease to optimize percutaneous coronary intervention (PCI) decisions. This tool is ideal for eliminating the need for invasive pressure wires and drugs while gaining comprehensive insights into lesion impact and functional patterns of CAD.

View FFRangio System →

Choose InVision Precision Cardiac Amyloid if…

Choose InVision Precision Cardiac Amyloid if your echocardiography lab aims to enhance the early and accurate detection of cardiac amyloidosis in patients presenting with heart failure symptoms. This AI-powered software is best suited for clinicians who want to leverage advanced technology to improve diagnostic precision from standard echocardiogram studies, thereby reducing misdiagnosis and improving patient outcomes.

View InVision Precision Cardiac Amyloid →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	FFRangio System	InVision Precision Cardiac Amyloid
Pricing	Contact vendor for pricing information.	Unknown
Deployment	SaaS, on-prem, hybrid	Cloud or on-premise
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FFRangio System

Tool A explicitly highlights an 'Intuitive user interface' and 'Seamless integration with cath lab boom and PACS'. These specific mentions suggest a strong focus on optimizing the user experience within a complex procedural environment, minimizing disruption for clinicians. While Tool B mentions integration into clinical workflows, it lacks similar specific descriptors regarding its user interface or ease of use.

Clinical Value

InVision Precision Cardiac Amyloid

Tool B addresses the critical issue of underdiagnosed, life-threatening cardiac amyloidosis, aiming for earlier detection and improved patient outcomes. Its evidence-based AI algorithm is peer-reviewed and published in JAMA Cardiology, providing strong validation of its clinical efficacy. While Tool A offers valuable wire-free FFR guidance, Tool B's potential to significantly impact patient survival by diagnosing a frequently missed condition gives it a higher clinical value.

Pricing & Value

InVision Precision Cardiac Amyloid

Tool B offers transparent starting pricing at '$49/mo' and provides options to 'Contact InVision Medical Technology for enterprise pricing and volume discounts'. This transparency allows potential customers to better assess initial costs and value. Tool A, in contrast, only states 'contact for pricing,' which provides no immediate insight into its cost structure.

Enterprise Readiness

InVision Precision Cardiac Amyloid

Tool B explicitly states it is 'hipaa_compliant', which is a fundamental requirement for healthcare enterprises handling Protected Health Information (PHI). Its Software as a Medical Device (SaMD) deployment model also generally offers greater flexibility for IT integration. Tool A's HIPAA compliance is 'unknown' from the provided data, although it is ISO 27001 certified for information security.

Innovation

FFRangio System

Tool A introduces 'wire-free and drug-free 3D FFR guidance,' directly eliminating the need for invasive pressure wires, drugs, or a guide catheter in coronary physiology assessment. This represents a significant procedural innovation that fundamentally changes how FFR is obtained. While Tool B's AI for detecting cardiac amyloidosis is innovative, Tool A's approach offers a more disruptive shift in an established interventional cardiology procedure.

Support & Docs

Tie

Neither tool's provided information nor readily available web searches offer specific details regarding their support infrastructure, documentation portals, service level agreements (SLAs), or training programs. Both likely offer standard customer support, but without further information, it is impossible to distinguish between them on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	FFRangio System	InVision Precision Cardiac Amyloid
Name	FFRangio System	InVision Precision Cardiac Amyloid
Company	CathWorks	InVision Medical Technology Corporation
Tagline	A New Era in Coronary Physiology	Improving the precision and accuracy of cardiovascular imaging.
Primary Specialty	Cardiology	Cardiology, Radiology
Key Function	Wire-free and drug-free 3D FFR guidance for optimizing PCI decisions in coronary artery disease.	AI-powered software for echocardiography to detect cardiac amyloidosis.

Videos

Demos, reviews, and walkthroughs featuring FFRangio System and InVision Precision Cardiac Amyloid.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of the FFRangio System and InVision Precision Cardiac Amyloid?

The CathWorks FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize PCI decisions for patients with coronary artery disease. InVision Precision Cardiac Amyloid is AI-powered software for echocardiography designed to detect cardiac amyloidosis, aiming for earlier detection and improved patient outcomes.

How do these tools integrate into existing clinical workflows?

The FFRangio System is deployed on-premise and integrates with cath lab equipment and C-arm angiography systems, streamlining procedural workflow. InVision Precision Cardiac Amyloid is a Software as a Medical Device (SaMD) that integrates into clinical workflows for echocardiography labs.

What types of imaging data do these AI tools analyze?

The FFRangio System analyzes routine angiograms to generate real-time FFRangio values and 3D models of the coronary tree. InVision Precision Cardiac Amyloid evaluates transthoracic echocardiogram studies, specifically apical-4-chamber and parasternal-long-axis view videos, for cardiac amyloidosis detection.

Do these tools offer benefits related to invasiveness or patient comfort?

The FFRangio System eliminates the need for invasive pressure wires, drugs, or a guide catheter for FFR assessment, potentially reducing radiation exposure and patient discomfort. InVision Precision Cardiac Amyloid aids in the non-invasive detection of cardiac amyloidosis using echocardiography, which is already a non-invasive imaging modality.

What are the key differences in the AI functionalities of these two systems?

The FFRangio System uses AI for quick angiogram analysis to provide real-time FFRangio values, simulated pullback curves, and a Lesion Impact feature for assessing residual ischemia. InVision Precision Cardiac Amyloid employs an evidence-based AI algorithm to detect cardiac amyloidosis and precisely assess wall thickness in echocardiogram studies.